BACKGROUND Microvascular invasion (MVI) is a major determinant of survival outcome for hepatocellular carcinoma (HCC). This study aimed to investigate the efficacy of postoperative adjuvant Sorafenib (PA-Sorafenib) in HCC patients with MVI after R0 liver resection (LR). METHODS The data of patients who underwent R0 LR for HCC with histologically confirmed MVI at the Eastern Hepatobiliary Surgery Hospital were retrospectively analyzed. The survival outcomes for patients who underwent PA-Sorafenib were compared with those who underwent R0 LR alone. Propensity score matching (PSM) analysis was performed. RESULTS 728 HCC patients had MVI in the resected specimens after R0 resection, with 581 who underwent LR alone and 147 patients who received in additional adjuvant sorafenib. PSM matched 113 patients in each of these two groups. The overall survival (OS) and recurrence free survival (RFS) were significantly better for patients in the PA-sorafenib group (for OS: before PSM, P = 0.003; after PSM, P = 0.007), (for RFS: before PSM, P = 0.029; after PSM, P = 0.001), respectively. Similar results were obtained in patients with BCLC 0-A, BCLC B and Child-Pugh A stages of disease. CONCLUSIONS PA-Sorafenib was associated with significantly better survival outcomes than LR alone for HCC patients with MVI.

中文翻译：

---

术后辅助索拉非尼可改善R0肝切除术后有微血管侵袭的肝细胞癌患者的生存结局：倾向评分匹配分析。

背景技术微血管浸润（MVI）是肝细胞癌（HCC）存活结果的主要决定因素。这项研究的目的是调查术后R0肝切除（LR）的HCC合并MVI的患者的术后佐剂Sorafenib（PA-Sorafenib）的疗效。方法回顾性分析经东方肝胆外科医院经组织学证实为MVI的HCC行R0 LR的患者的资料。将接受PA-索拉非尼的患者与仅接受R0 LR的患者的生存结果进行了比较。进行倾向得分匹配（PSM）分析。结果728例HCC患者在R0切除后的切除标本中有MVI，其中581例接受了LR，另外147例接受了辅助的索拉非尼治疗。在这两组中，PSM匹配了113名患者。PA-索拉非尼组的患者的总生存期（OS）和无复发生存期（RFS）明显更好（OS：PSM之前，P = 0.003; PSM之后，P = 0.007），（RFS：PSM之前， P = 0.029；在PSM之后，P = 0.001）。在患有BCLC 0-A，BCLC B和Child-Pugh A分期的患者中获得了相似的结果。结论对于MVI的HCC患者，PA-索拉非尼的生存结局明显优于仅LR。